DexCom DXCM Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $930.4M+73.8% | $836.3M+45.1% | $720.7M+5.9% | $571.5M-14.3% | $535.2M-16.3% | ||
| $258.9M+15.0% | $251.8M+15.7% | $244.4M+15.1% | $236.1M+15.0% | $225.2M+14.4% | ||
| $168.7M+1.9% | $159.6M-6.3% | $167.9M+2.4% | $166.2M+4.1% | $165.6M+7.1% | ||
| $188.3M— | $182.2M— | —— | —— | —— | ||
| —— | —— | —— | $396.5M+103% | $178.1M-48.0% | ||
| $135.1M+344% | $63.7M+614% | $13.2M-83.4% | -$18.5M-112% | -$55.3M-124% | ||
| —— | —— | —— | $409.2M+1.9% | $247.5M-52.3% | ||
| $10.1M— | $56.6M— | —— | —— | —— | ||
| -$19.7M— | $14.8M— | —— | —— | —— | ||
| -$6.9M+22.5% | -$11.5M-36.9% | -$13M-41.3% | -$5.3M+31.2% | -$8.9M-1,383% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $1.78B+84.9% | $1.44B+45.6% | $1.45B+76.2% | $987.7M+10.8% | $964.1M+20.2% | ||
| $353.1M-9.2% | $363.5M+1.3% | $386.2M+34.7% | $416.9M+84.6% | $388.9M+77.7% | ||
| $1.47B-28.0% | $1.25B-51.6% | $1.74B-25.5% | $1.87B-33.8% | $2.05B-39.5% | ||
| $1.98B-15.7% | $2.16B-23.4% | $2.16B-31.2% | $2.32B-26.9% | $2.35B-30.2% | ||
| -$1.1M-106% | -$600K-104% | $15.9M+175% | $12.9M+187% | $18.3M+536% | ||
| —— | —— | —— | —— | -$182.1M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$7.2M-20.0% | -$7M+46.2% | -$6.7M-3.1% | -$6.3M+1.6% | -$6M+1.6% | ||
| -$1.72B-137% | -$1.69B-130% | -$165.8M+87.9% | -$727.3M+42.6% | -$727M-124% | ||
| $17.5M+1,446% | $22.6M+405% | $7.6M-23.2% | $16.2M+836% | -$1.3M+61.8% | ||
| —— | —— | —— | —— | —— | ||
| —— | $11.4M0.0% | $11.4M-2.1% | $11.4M-4.2% | $11.4M-6.2% | ||
| —— | $94.4M-52.3% | $120.3M-40.3% | $146.2M-28.7% | $172.1M-17.5% | ||
| —— | —— | —— | —— | —— | ||
| $10.1M— | $56.6M— | —— | —— | —— | ||
| $7.5M— | $7.1M— | $8M— | —— | —— | ||
| -$19.7M— | $14.8M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $6.4M-14.7% | $7.3M-2.7% | $7.5M-1.3% | $7.5M-5.1% | $7.5M-8.5% | ||
| -$1.1M-106% | -$600K-104% | $15.9M+175% | $12.9M+187% | $18.3M+536% | ||
| —— | —— | —— | —— | —— | ||
| $1.98B-15.7% | $2.16B-23.4% | $2.16B-31.2% | $2.32B-26.9% | $2.35B-30.2% | ||
| -$7.2M-20.0% | -$7M+46.2% | -$6.7M-3.1% | -$6.3M+1.6% | -$6M+1.6% | ||
| —— | $1.21B— | $905.63M— | $603.75M— | $301.88M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $1.43B+149% | $1.08B+70.8% | $1.06B+98.5% | $570.8M-14.2% | $575.2M-1.4% | ||
| $1.43B+149% | $1.08B+70.8% | $1.06B+98.5% | $570.8M-14.2% | $575.2M-1.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does DexCom generate?
- DexCom (DXCM) generated $1.8B in operating cash flow over the trailing twelve months.
- What is DexCom's free cash flow?
- After $353.1M of capital expenditures, DexCom's free cash flow was $1.4B over the trailing twelve months, up 148.5% year over year.
- Where does DexCom's cash flow data come from?
- Every line is extracted from DexCom's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
